Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyung-Hun Lee

Showing results (241-250 of 248) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 248 results.
Cancer Research and Treatment|August 20, 2024
Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year ExperienceJiwon Koh, Jinyong Kim, Go-Un Woo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 5, 2019
Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint InhibitorsBhumsuk Keam, Chang Kyung Kang, Kang Il Jun, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2024
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort StudyRyan Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
Breast Cancer (Tokyo, Japan)|June 24, 2026
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialTakashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, et al.
NPJ Breast Cancer|August 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerEmi Noguchi, Takashi Yamanaka, Hirofumi Mukai, et al.
BMC Cancer|August 10, 2025
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)Jieun Lee, Hee Kyung Ahn, Kyung-Hun Lee, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Genome Medicine|July 20, 2023
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerYeon Hee Park, Seock-Ah Im, Kyunghee Park, et al.
Pageof 25

Showing results (241-250 of 248) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 248 results.
Cancer Research and Treatment|August 20, 2024
Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year ExperienceJiwon Koh, Jinyong Kim, Go-Un Woo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 5, 2019
Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint InhibitorsBhumsuk Keam, Chang Kyung Kang, Kang Il Jun, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2024
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort StudyRyan Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
Breast Cancer (Tokyo, Japan)|June 24, 2026
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialTakashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, et al.
NPJ Breast Cancer|August 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerEmi Noguchi, Takashi Yamanaka, Hirofumi Mukai, et al.
BMC Cancer|August 10, 2025
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)Jieun Lee, Hee Kyung Ahn, Kyung-Hun Lee, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Genome Medicine|July 20, 2023
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerYeon Hee Park, Seock-Ah Im, Kyunghee Park, et al.
Pageof 25